Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Paratek Pharmaceuticals Inc    PRTK

PARATEK PHARMACEUTICALS INC (PRTK)
My previous session
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
OFFRE
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/17/2018 09/18/2018 09/19/2018 09/20/2018 09/21/2018 Date
9.05(c) 9.1(c) 9.15(c) 9.25(c) 9.65(c) Last
516 700 267 026 170 142 255 641 556 279 Volume
-3.21% +0.55% +0.55% +1.09% +4.32% Change
More quotes
Financials (USD)
Sales 2018 13,7 M
EBIT 2018 -99,3 M
Net income 2018 -107 M
Debt 2018 -
Yield 2018 -
Sales 2019 42,3 M
EBIT 2019 -87,6 M
Net income 2019 -101 M
Debt 2019 12,0 M
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
EV / Sales2018 21,4x
EV / Sales2019 7,23x
Capitalization 293 M
More Financials
Company
Paratek Pharmaceuticals, Inc. engages in the development and commercialization of therapies based upon tetracycline chemistry.Its products include Omadacycline and Sarecycline, which are used for the treatment of serious community-acquired bacterial infections, including community-acquired... 
More about the company
Surperformance© ratings of Paratek Pharmaceuticals In
Trading Rating : Investor Rating :
More Ratings
Latest news on PARATEK PHARMACEUTICALS IN
09/07PARATEK PHARMACEUTICALS : Announces Inducement Grants under NASDAQ Listing Rule ..
AQ
09/05PARATEK PHARMACEUTICALS : Announces Inducement Grants under NASDAQ Listing Rule ..
AQ
09/04PARATEK PHARMACEUTICALS : Announces Inducement Grants under NASDAQ Listing Rule ..
AQ
08/31PARATEK PHARMACEUTICALS : to Present at Baird's 2018 Global Healthcare Conferenc..
AQ
08/29Paratek Pharmaceuticals to Present at Baird's 2018 Global Healthcare Conferen..
GL
08/16PARATEK PHARMACEUTICALS : FDA Advisory Committee Recommends Approval of Paratek'..
AQ
08/10PARATEK PHARMACEUTICALS : FDA Advisors Like Novel Tetracycline Analogue
AQ
08/08PARATEK PHARMACEUTICALS, INC. : Other Events, Financial Statements and Exhibits ..
AQ
08/08FDA Advisory Committee Recommends Approval of Paratek’s Omadacycline
GL
08/08Paratek Pharmaceuticals Stock Trading Halted Today; FDA Advisory Committee to..
GL
More news
Sector news : Bio Therapeutic Drugs
09/19NOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug in First European Setback -..
DJ
09/19NOVARTIS : U.K. Pulls Brakes on Novartis' CAR-T Drug for Some Patients Despite D..
DJ
09/19GILEAD SCIENCES : UK rejects adult Novartis CAR-T therapy, after 'yes' in kids
RE
09/18REGENERON PHARMACEUTICALS : Sanofi pledges to keep up its restructuring efforts
RE
09/14Allogene, Which Announced Pfizer Agreement in April, Discloses IPO Plans
DJ
More sector news : Bio Therapeutic Drugs
Latest Tweets
09/21TREND REVERSAL UP ALERT: $PRTK PARATEK PHARMACEUTICALS ? TradeIdeas via  
08/27Monday's Top Analyst Upgrades and Downgrades PART 2: AK Steel, Bloom Energy, ..
1
08/27Premarket analyst action - healthcare  
08/22$5.89 Million in Sales Expected for Paratek Pharmaceuticals Inc $PRTK This Qu.. 
08/22Paratek Pharmaceuticals Inc $PRTK Expected to Announce Quarterly Sales of $5... 
More tweets
Qtime:24
News from SeekingAlpha
09/07The Waiting Is The Hardest Part - The Idea Guide 
08/27Premarket analyst action - healthcare 
08/26For Paratek, Only A Matter Of Time Before Stock Rises.Eventually 
08/14Tracking Seth Klarman's Baupost Group Holdings - Q2 2018 Update 
08/13BIOTECH ANALYSIS CENTRAL PHARMA NEWS : Gemphire Pulls Plug, Ampio's FDA Despair,.. 
Chart PARATEK PHARMACEUTICALS INC
Duration : Period :
Paratek Pharmaceuticals Inc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends PARATEK PHARMACEUTICALS IN
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Average target price 31,5 $
Spread / Average Target 241%
EPS Revisions
Managers
NameTitle
Michael F. Bigham Chairman & Chief Executive Officer
Evan Loh President, COO, Director & Chief Medical Officer
Douglas W. Pagán Chief Financial & Accounting Officer
Paul McGovern Vice President-Clinical & Medical Affairs
Thomas John Dietz Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
PARATEK PHARMACEUTICALS INC-46.09%293
GILEAD SCIENCES5.40%97 887
VERTEX PHARMACEUTICALS20.46%46 021
REGENERON PHARMACEUTICALS3.00%41 426
NEUROCRINE BIOSCIENCES, INC.54.17%10 822
GENMAB2.04%10 170